Company latest

News and press

April 2015

Focus successful in UK litigation against Novartis concerning VolezeĀ® Rivastigmine Transdermal Patches

Company performance and financials

Focus has grown significantly since it was started as shown by the financials below.  

The Company continues to invest approximately 50% of expenditure in new product development projects.  This continued investment in the pipeline, and a fairly consistent overhead base means that almost all new product profits increase the operating profit directly.